Leonardo C Clavijo
Overview
Explore the profile of Leonardo C Clavijo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhillon A, Caro J, Choi J, Caro J, Rowe V, Kumar S, et al.
Cardiovasc Revasc Med
. 2024 Dec;
PMID: 39638643
Background: Chronic limb-threatening ischemia (CLTI) is associated with increased risk of major adverse cardiac and limb events (MACLE). In patients with peripheral arterial disease (PAD), evolocumab is associated with decreased...
2.
Menard M, Farber A, Doros G, McGinigle K, Chisci E, Clavijo L, et al.
J Vasc Surg
. 2024 Jul;
80(6):1755-1765.e4.
PMID: 39069016
Objective: Sustained clinical and hemodynamic benefit after revascularization for chronic limb-threatening ischemia (CLTI) is needed to resolve symptoms and prevent limb loss. We sought to compare rates of clinical and...
3.
Menard M, Jaff M, Farber A, Rosenfield K, Conte M, White C, et al.
J Vasc Surg
. 2023 May;
78(3):711-718.e5.
PMID: 37201761
Objectives: The use of optimal medical therapy (OMT) in patients with chronic limb-threatening ischemia (CLTI) has not been well-studied. The Best Endovascular vs Best Surgical Therapy in Patients with CLTI...
4.
Clavijo L, Caro J, Choi J, Caro J, Tun H, Rowe V, et al.
Cardiovasc Revasc Med
. 2023 May;
55:1-5.
PMID: 37142533
Objective: To test the hypothesis that in patients with peripheral arterial disease (PAD) and claudication, treated with maximal tolerated statin therapy, the addition of a monthly subcutaneous injection of evolocumab...
5.
Siracuse J, Rowe V, Menard M, Rosenfield K, Conte M, Powell R, et al.
J Vasc Surg
. 2022 Nov;
77(4):1099-1106.e4.
PMID: 36435274
Objective: The WIfI (Wound, Ischemia, foot Infection) stage measures the extent of wounds, ischemia, and foot infection in patients with chronic limb threatening ischemia (CLTI) and has been associated with...
6.
Farber A, Menard M, Conte M, Kaufman J, Powell R, Choudhry N, et al.
N Engl J Med
. 2022 Nov;
387(25):2305-2316.
PMID: 36342173
Background: Patients with chronic limb-threatening ischemia (CLTI) require revascularization to improve limb perfusion and thereby limit the risk of amputation. It is uncertain whether an initial strategy of endovascular therapy...
7.
Wu Z, Lin J, Yang W, Jiang N, Huang N, Clavijo L
BMC Pulm Med
. 2021 Mar;
21(1):77.
PMID: 33663424
Background: The purpose of this study was to assess the safety and efficacy of percutaneous transcatheter embolization (TCE) for the treatment of pulmonary arteriovenous malformations (PAVMs). Methods: Forty-three consecutive patients...
8.
Rusia A, Kita K, Shah S, Roy D, Zhang Y, Nattiv J, et al.
J Innov Card Rhythm Manag
. 2020 Jun;
10(8):3785-3789.
PMID: 32477745
A common dilemma facing physicians treating patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) is the management of oral anticoagulation (OAC) therapy, because there is also...
9.
Raj L, Upadyhay R, Clavijo L, Tun H, Mehra A, Hindoyan A, et al.
Cardiovasc Revasc Med
. 2020 May;
21(12):1489-1492.
PMID: 32448777
Background: Drug eluting stents (DES) are used in the majority of patients undergoing percutaneous coronary intervention (PCI). Factors associated with the use of bare metal stents (BMS) for patients undergoing...
10.
Zhang L, Saldana-Ruiz N, Elsayed R, Armstrong D, Shin L, Magee G, et al.
Ann Vasc Surg
. 2020 Feb;
66:614-620.
PMID: 32027986
Background: Management of patients with chronic limb-threatening ischemia (CLTI) and extensive foot necrosis presents a challenge for limb salvage. Our study evaluates preoperative risk factors that contributed to durability and...